JPH11507203A - 脊椎動物Ｓｅｒｒａｔｅ遺伝子のヌクレオチドおよびタンパク質配列およびそれらに基づく方法 - Google Patents

Info

Publication number

JPH11507203A

JPH11507203A JP8527061A JP52706196A JPH11507203A JP H11507203 A JPH11507203 A JP H11507203A JP 8527061 A JP8527061 A JP 8527061A JP 52706196 A JP52706196 A JP 52706196A JP H11507203 A JPH11507203 A JP H11507203A

Authority

JP

Japan

Prior art keywords

serrate

protein

fragment

nucleic acid

notch

Prior art date

1995-03-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 108010036039 Serrate-Jagged Proteins Proteins 0.000 title claims abstract description 425
• 108090000623 proteins and genes Chemical group 0.000 title claims abstract description 234
• 102000004169 proteins and genes Human genes 0.000 title claims abstract description 148
• 241000251539 Vertebrata <Metazoa> Species 0.000 title claims abstract description 117
• 238000000034 method Methods 0.000 title claims abstract description 116
• 239000002773 nucleotide Substances 0.000 title claims abstract description 69
• 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 67
• 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims abstract description 384
• 239000012634 fragment Substances 0.000 claims abstract description 145
• 241000282414 Homo sapiens Species 0.000 claims abstract description 79
• 230000027455 binding Effects 0.000 claims abstract description 73
• 238000011282 treatment Methods 0.000 claims abstract description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
• 230000003834 intracellular effect Effects 0.000 claims abstract description 18
• 102000003839 Human Proteins Human genes 0.000 claims abstract description 6
• 108090000144 Human Proteins Proteins 0.000 claims abstract description 6
• 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
• 108010070047 Notch Receptors Proteins 0.000 claims description 134
• 102000005650 Notch Receptors Human genes 0.000 claims description 130
• 150000001413 amino acids Chemical class 0.000 claims description 126
• 150000007523 nucleic acids Chemical class 0.000 claims description 112
• 230000014509 gene expression Effects 0.000 claims description 102
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 101
• 102000039446 nucleic acids Human genes 0.000 claims description 94
• 108020004707 nucleic acids Proteins 0.000 claims description 94
• 108020004414 DNA Proteins 0.000 claims description 55
• 201000010099 disease Diseases 0.000 claims description 50
• 208000035475 disorder Diseases 0.000 claims description 48
• 206010028980 Neoplasm Diseases 0.000 claims description 40
• 108091034117 Oligonucleotide Proteins 0.000 claims description 30
• 230000000694 effects Effects 0.000 claims description 30
• 201000011510 cancer Diseases 0.000 claims description 24
• 239000000203 mixture Substances 0.000 claims description 24
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
• 239000013612 plasmid Substances 0.000 claims description 22
• 238000004519 manufacturing process Methods 0.000 claims description 19
• 108091026890 Coding region Proteins 0.000 claims description 17
• 108700024228 Drosophila Ser Proteins 0.000 claims description 16
• 210000003169 central nervous system Anatomy 0.000 claims description 15
• 230000002159 abnormal effect Effects 0.000 claims description 13
• 230000000295 complement effect Effects 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 13
• 230000002265 prevention Effects 0.000 claims description 13
• 230000036210 malignancy Effects 0.000 claims description 12
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
• 230000005714 functional activity Effects 0.000 claims description 10
• 108020001507 fusion proteins Proteins 0.000 claims description 9
• 102000037865 fusion proteins Human genes 0.000 claims description 9
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
• 201000010881 cervical cancer Diseases 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 241000255601 Drosophila melanogaster Species 0.000 claims description 2
• 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
• 241001599018 Melanogaster Species 0.000 claims description 2
• 201000010208 Seminoma Diseases 0.000 claims description 2
• 229940116977 epidermal growth factor Drugs 0.000 claims description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
• 230000001747 exhibiting effect Effects 0.000 claims 3
• 230000010005 growth-factor like effect Effects 0.000 claims 3
• 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
• 201000001441 melanoma Diseases 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 abstract description 114
• 241000287828 Gallus gallus Species 0.000 abstract description 29
• 241000699666 Mus <mouse, genus> Species 0.000 abstract description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 8
• 235000018417 cysteine Nutrition 0.000 abstract description 8
• 239000012528 membrane Substances 0.000 abstract description 7
• 241000269370 Xenopus <genus> Species 0.000 abstract description 4
• 238000003745 diagnosis Methods 0.000 abstract description 4
• 210000004027 cell Anatomy 0.000 description 115
• 235000001014 amino acid Nutrition 0.000 description 92
• 229940024606 amino acid Drugs 0.000 description 92
• 239000003814 drug Substances 0.000 description 66
• 239000002299 complementary DNA Substances 0.000 description 58
• 229940124597 therapeutic agent Drugs 0.000 description 49
• 238000003556 assay Methods 0.000 description 41
• 239000013598 vector Substances 0.000 description 33
• 230000006870 function Effects 0.000 description 32
• 238000003752 polymerase chain reaction Methods 0.000 description 31
• 230000000692 anti-sense effect Effects 0.000 description 29
• 235000013330 chicken meat Nutrition 0.000 description 28
• 238000000338 in vitro Methods 0.000 description 26
• 210000001519 tissue Anatomy 0.000 description 26
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
• 230000001225 therapeutic effect Effects 0.000 description 24
• 230000003211 malignant effect Effects 0.000 description 23
• 239000000523 sample Substances 0.000 description 22
• 238000009396 hybridization Methods 0.000 description 21
• 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 description 19
• 102000056036 human JAG1 Human genes 0.000 description 19
• 238000001727 in vivo Methods 0.000 description 18
• 230000001105 regulatory effect Effects 0.000 description 18
• 238000011161 development Methods 0.000 description 17
• 230000018109 developmental process Effects 0.000 description 17
• 210000000653 nervous system Anatomy 0.000 description 17
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 239000005557 antagonist Substances 0.000 description 15
• 238000010367 cloning Methods 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 108020004999 messenger RNA Proteins 0.000 description 15
• 230000014616 translation Effects 0.000 description 15
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 14
• 102000049546 Jagged-2 Human genes 0.000 description 14
• 238000001990 intravenous administration Methods 0.000 description 14
• 239000013615 primer Substances 0.000 description 14
• 108090000765 processed proteins & peptides Proteins 0.000 description 14
• 108700003489 Jagged-2 Proteins 0.000 description 13
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
• 238000003018 immunoassay Methods 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 102000049556 Jagged-1 Human genes 0.000 description 11
• 108700003486 Jagged-1 Proteins 0.000 description 11
• 239000013604 expression vector Substances 0.000 description 11
• 238000007901 in situ hybridization Methods 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 108010076504 Protein Sorting Signals Proteins 0.000 description 10
• 241000700605 Viruses Species 0.000 description 10
• 239000000556 agonist Substances 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 238000003776 cleavage reaction Methods 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 230000003902 lesion Effects 0.000 description 10
• 230000004048 modification Effects 0.000 description 10
• 238000012986 modification Methods 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 230000036961 partial effect Effects 0.000 description 10
• 230000007017 scission Effects 0.000 description 10
• 238000013519 translation Methods 0.000 description 10
• 102000018386 EGF Family of Proteins Human genes 0.000 description 9
• 108010066486 EGF Family of Proteins Proteins 0.000 description 9
• -1 For example Proteins 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 102000053602 DNA Human genes 0.000 description 8
• 108700026244 Open Reading Frames Proteins 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 210000003716 mesoderm Anatomy 0.000 description 8
• 108091008146 restriction endonucleases Proteins 0.000 description 8
• 238000012216 screening Methods 0.000 description 8
• 210000000278 spinal cord Anatomy 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 230000017423 tissue regeneration Effects 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 7
• 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 7
• 108020004511 Recombinant DNA Proteins 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 108700041286 delta Proteins 0.000 description 7
• 230000001605 fetal effect Effects 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 206010020718 hyperplasia Diseases 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 230000001272 neurogenic effect Effects 0.000 description 7
• 210000002569 neuron Anatomy 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 238000010561 standard procedure Methods 0.000 description 7
• 206010058314 Dysplasia Diseases 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
• 239000000853 adhesive Substances 0.000 description 6
• 230000001070 adhesive effect Effects 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 210000003981 ectoderm Anatomy 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 210000003128 head Anatomy 0.000 description 6
• 238000000099 in vitro assay Methods 0.000 description 6
• 238000007913 intrathecal administration Methods 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 210000000982 limb bud Anatomy 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 230000004807 localization Effects 0.000 description 6
• 210000001161 mammalian embryo Anatomy 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 230000001855 preneoplastic effect Effects 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 206010054949 Metaplasia Diseases 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 238000007818 agglutination assay Methods 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 230000003042 antagnostic effect Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 238000013270 controlled release Methods 0.000 description 5
• 210000000695 crystalline len Anatomy 0.000 description 5
• 230000003412 degenerative effect Effects 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 210000002257 embryonic structure Anatomy 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 210000003734 kidney Anatomy 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 230000015689 metaplastic ossification Effects 0.000 description 5
• 244000005700 microbiome Species 0.000 description 5
• 238000010369 molecular cloning Methods 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 210000004940 nucleus Anatomy 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 150000003839 salts Chemical group 0.000 description 5
• 238000004062 sedimentation Methods 0.000 description 5
• 210000002027 skeletal muscle Anatomy 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 241000972773 Aulopiformes Species 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 229920001917 Ficoll Polymers 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108010029755 Notch1 Receptor Proteins 0.000 description 4
• 102000001759 Notch1 Receptor Human genes 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 230000002776 aggregation Effects 0.000 description 4
• 238000004220 aggregation Methods 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 230000008614 cellular interaction Effects 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 235000013399 edible fruits Nutrition 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 239000000411 inducer Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 210000001259 mesencephalon Anatomy 0.000 description 4
• 210000002161 motor neuron Anatomy 0.000 description 4
• 230000001613 neoplastic effect Effects 0.000 description 4
• 238000007899 nucleic acid hybridization Methods 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 230000037452 priming Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 235000019515 salmon Nutrition 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 230000001568 sexual effect Effects 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 3
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 201000004384 Alopecia Diseases 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• 241000271566 Aves Species 0.000 description 3
• 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 208000002260 Keloid Diseases 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 102000018697 Membrane Proteins Human genes 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 238000000636 Northern blotting Methods 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 241000405965 Scomberomorus brasiliensis Species 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 208000009956 adenocarcinoma Diseases 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 230000007882 cirrhosis Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 239000013599 cloning vector Substances 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000003676 hair loss Effects 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 238000007914 intraventricular administration Methods 0.000 description 3
• 210000001117 keloid Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 208000005264 motor neuron disease Diseases 0.000 description 3
• 210000000276 neural tube Anatomy 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 229920003023 plastic Polymers 0.000 description 3
• 239000004033 plastic Substances 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000001850 reproductive effect Effects 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 241000255925 Diptera Species 0.000 description 2
• 108700007800 Drosophila N Proteins 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 208000000571 Fibrocystic breast disease Diseases 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010023330 Keloid scar Diseases 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
• 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
• 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 2
• 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 2
• 108010029751 Notch2 Receptor Proteins 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 108020004518 RNA Probes Proteins 0.000 description 2
• 239000003391 RNA probe Substances 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 102100026966 Thrombomodulin Human genes 0.000 description 2
• 108010079274 Thrombomodulin Proteins 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 241000209140 Triticum Species 0.000 description 2
• 235000021307 Triticum Nutrition 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 108700024209 Xenopus jag1 Proteins 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 210000003837 chick embryo Anatomy 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 239000004020 conductor Substances 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 210000002451 diencephalon Anatomy 0.000 description 2
• 210000003027 ear inner Anatomy 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 238000010230 functional analysis Methods 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000012817 gel-diffusion technique Methods 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000000951 immunodiffusion Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000004777 loss-of-function mutation Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 210000001087 myotubule Anatomy 0.000 description 2
• 210000001020 neural plate Anatomy 0.000 description 2
• 230000004766 neurogenesis Effects 0.000 description 2
• 230000006764 neuronal dysfunction Effects 0.000 description 2
• 230000036963 noncompetitive effect Effects 0.000 description 2
• 208000019180 nutritional disease Diseases 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 210000002729 polyribosome Anatomy 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000003449 preventive effect Effects 0.000 description 2
• 201000002241 progressive bulbar palsy Diseases 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 210000001202 rhombencephalon Anatomy 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 210000000697 sensory organ Anatomy 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000012916 structural analysis Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 108091005703 transmembrane proteins Proteins 0.000 description 2
• 102000035160 transmembrane proteins Human genes 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
• SQRDRPSVGROPHX-UHFFFAOYSA-N 2,3,3-triiodoprop-2-en-1-ol Chemical compound OCC(I)=C(I)I SQRDRPSVGROPHX-UHFFFAOYSA-N 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 206010001907 Amblyopia alcohol Diseases 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 101100448366 Arabidopsis thaliana GH3.12 gene Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000238421 Arthropoda Species 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 208000005692 Bloom Syndrome Diseases 0.000 description 1
• 208000013165 Bowen disease Diseases 0.000 description 1
• 208000019337 Bowen disease of the skin Diseases 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006237 Breast dysplasia Diseases 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 208000001843 Carotid Body Tumor Diseases 0.000 description 1
• 208000037211 Carotid body tumour Diseases 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
• 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• LMKYZBGVKHTLTN-NKWVEPMBSA-N D-nopaline Chemical compound NC(=N)NCCC[C@@H](C(O)=O)N[C@@H](C(O)=O)CCC(O)=O LMKYZBGVKHTLTN-NKWVEPMBSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
• 238000007399 DNA isolation Methods 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 206010011953 Decreased activity Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 208000005917 Exostoses Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 206010016880 Folate deficiency Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 208000000321 Gardner Syndrome Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 101150031823 HSP70 gene Proteins 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 101000801209 Homo sapiens Transducin-like enhancer protein 4 Proteins 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 208000032984 Intraoperative Complications Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 102000000853 LDL receptors Human genes 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100397589 Mus musculus Jag1 gene Proteins 0.000 description 1
• 101100294417 Mus musculus Notch1 gene Proteins 0.000 description 1
• 101100366940 Mus musculus Stom gene Proteins 0.000 description 1
• UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 108091007369 NEUR proteins Proteins 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 102000001756 Notch2 Receptor Human genes 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
• 208000006994 Precancerous Conditions Diseases 0.000 description 1
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101710170213 Protein jagged-2 Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 101100348838 Rattus norvegicus Notch1 gene Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 206010039509 Scab Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 1
• 206010058571 Spinal cord infarction Diseases 0.000 description 1
• 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 241000906446 Theraps Species 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 241001504592 Trachurus trachurus Species 0.000 description 1
• 102100033763 Transducin-like enhancer protein 4 Human genes 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000010045 Wernicke encephalopathy Diseases 0.000 description 1
• 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000004523 agglutinating effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 210000001643 allantois Anatomy 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
• 101150010487 are gene Proteins 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 229940019700 blood coagulation factors Drugs 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 201000008274 breast adenocarcinoma Diseases 0.000 description 1
• 208000011803 breast fibrocystic disease Diseases 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 238000003352 cell adhesion assay Methods 0.000 description 1
• 230000008568 cell cell communication Effects 0.000 description 1
• 230000023402 cell communication Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 230000021617 central nervous system development Effects 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 210000001608 connective tissue cell Anatomy 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000007821 culture assay Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical class NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 101150052825 dnaK gene Proteins 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 230000008143 early embryonic development Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 201000006828 endometrial hyperplasia Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 230000009144 enzymatic modification Effects 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 230000008472 epithelial growth Effects 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000003746 feather Anatomy 0.000 description 1
• 229960004887 ferric hydroxide Drugs 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000010359 gene isolation Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000001295 genetical effect Effects 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000006377 glucose transport Effects 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000035931 haemagglutination Effects 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000035992 intercellular communication Effects 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 230000007654 ischemic lesion Effects 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 230000023886 lateral inhibition Effects 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000001704 mesoblast Anatomy 0.000 description 1
• 210000002783 mesonephros Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 108010065781 myosin light chain 2 Proteins 0.000 description 1
• XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000000118 neural pathway Anatomy 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 208000030212 nutrition disease Diseases 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000000243 photosynthetic effect Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000013197 protein A assay Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 102220201851 rs143406017 Human genes 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229940043230 sarcosine Drugs 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 230000008470 skin growth Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000002023 somite Anatomy 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 210000003863 superior colliculi Anatomy 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 235000002374 tyrosine Nutrition 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000009941 weaving Methods 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1